Patients and providers are having to pay more toward their health plans due to these common radiology services charging more than needed.
Health insurance companies are overpaying for some common radiology services, leading to higher costs for patients and providers, according information shared from a study by Michigan State University (MSU).
Published in the journal Radiology, researchers found that the maximum negotiated price for shoppable radiology services, on average, was 3.8 times the minimum negotiated price in the same hospital among various insurance companies and 1.2 times the minimum negotiated price in the same hospital among the same insurance company’s multiple health plans.
“Many commercial plans are leaving money on the table when negotiating prices with hospitals, especially for expensive CT and MRI scans,” said study co-author Ge Bai, a former doctoral student in MSU's Eli Broad College of Business and current professor of accounting, and health policy and management at Johns Hopkins University, in a release. “High prices paid by commercial plans eventually come back to bite patients and providers through high premiums and out-of-pocket costs.”
The study found that the multiple insurance plans in contract with hospitals negotiated different prices for the same services within the same hospital, and even negotiated different prices across their own various health plans.
Researchers studied commercial negotiated prices from private payers for the 13 radiology services. Services that require high-cost equipment like a CT scanner and MRI, had more wide cost variations and higher prices relative to Medicare when compared to other radiology services, according to the information shared.
Out of the reviewed services, brain CT scans had the greatest price gap, in which 25% of hospital-insurance company pairs had set their maximum negotiated price at more than 2.4 times their minumum price.
Bai said, because of the Price Transparency Rule disclosing U.S. hospital pricing information, it "took the blindfold off the eyes of commercial payers, forcing them to recognize the fact that they are often paying too much."
“Equipped with pricing information, radiologists can change the landscape of care delivery to benefit patients and payers.”
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
FDA Accepts Tabelecleucel BLA; Priority Review Granted for Post-Transplant Disease Therapy
July 24th 2025The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Read More